Canadian Cancer Society logo

Eye cancer

You are here: 

Follow-up after treatment for eye cancer

Eye cancer behaves differently in each person, and a standard follow-up schedule would not work for everyone. People with eye cancer should talk to their doctor about a follow-up plan that suits their individual situation. Follow-up care is often shared among the cancer specialists (oncologists), the family doctor and eye specialists.

After treatment has ended, new symptoms and symptoms that don’t go away should be reported to the doctor without waiting for the next scheduled appointment. These may include:

  • change or loss of vision
  • eye pain

Schedule

Follow-up after eye cancer treatment varies. Follow-up after treatment is tailored to the individual. Follow-up visits are usually scheduled:

  • every 3–6 months after initial treatment
  • if no further changes are seen, then every 6 months

Procedures

During a follow-up visit, the doctor usually asks questions about the side effects of treatment and how the person is coping. The doctor will also ask people who have an artificial eye (prosthesis) if they are having any problems with it. The doctor may do a complete physical examination, including:

  • an eye examination and vision test

Tests may be ordered as part of follow-up or if the doctor suspects the cancer has come back (has recurred).

  • blood chemistry test to check liver function
  • ultrasound of the liver if liver function tests suggest liver metastasis
  • computed tomography (CT) scan
  • magnetic resonance imaging (MRI)
  • chest x-ray to check for metastasis in the lung

If a recurrence is found during follow-up, the oncology team will assess the person with cancer to determine the best treatment options.

See a list of questions to ask your doctor about follow-up after treatment.

Stories

Paulette Hicks A random act of kindness during one of the most vulnerable times in someone’s life can be powerful.

Read Paulette's story

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more